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already known to be associated with other syndromic neu-
rodevelopmental disorders. We determined that the other 
patients harbored mutations in genes that have not previ-
ously been linked to RTT or other neurodevelopmental 
syndromes, such as the ankyrin repeat containing protein 
ANKRD31 or the neuronal acetylcholine receptor subunit 
alpha-5 (CHRNA5). Furthermore, worm assays demon-
strated that mutations in the studied candidate genes caused 
locomotion defects. Our findings indicate that mutations in 
a variety of genes contribute to the development of RTT-
like phenotypes.
Introduction
Rett syndrome (RTT, MIM 312750) is a postnatal pro-
gressive neurodevelopmental disorder (NDD), originally 
Abstract Classical Rett syndrome (RTT) is a neurode-
velopmental disorder where most of cases carry MECP2 
mutations. Atypical RTT variants involve mutations in 
CDKL5 and FOXG1. However, a subset of RTT patients 
remains that do not carry any mutation in the described 
genes. Whole exome sequencing was carried out in a cohort 
of 21 female probands with clinical features overlapping 
with those of RTT, but without mutations in the customar-
ily studied genes. Candidates were functionally validated 
by assessing the appearance of a neurological phenotype 
in Caenorhabditis elegans upon disruption of the corre-
sponding ortholog gene. We detected pathogenic variants 
that accounted for the RTT-like phenotype in 14 (66.6 %) 
patients. Five patients were carriers of mutations in genes 
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described in the 1960s by Andreas Rett (Rett 1966), 
that most frequently manifests itself in girls during 
early childhood, with an incidence of approximately 1 
in 10,000 live births (Chahrour and Zoghbi 2007). RTT 
patients are asymptomatic during the first 6–18 months 
of life, but gradually develop severe motor, cognitive, 
and behavioral abnormalities that persist for life. It is the 
second most common cause of intellectual disability in 
females after Down’s syndrome (Chahrour and Zoghbi 
2007). Around 90 % of the cases are explained by more 
than 800 reported mutations in the methyl CpG-binding 
protein 2 gene (MECP2) (RettBASE: MECP2 Variation 
Database) (Christodoulou et al. 2003), which is located in 
the X chromosome and which causes most of the classi-
cal or typical forms of RTT (Chahrour and Zoghbi 2007), 
and it was originally identified as encoding a protein 
that binds to methylated DNA (Lewis et al. 1992). Indi-
viduals affected by atypical or variant RTT present with 
many of the clinical features of RTT, but do not neces-
sarily have all of the classic characteristics of the disor-
der (Neul et al. 2010). Approximately 8 % of classic RTT 
and 42 % of variant RTT patients are MECP2 mutation-
negative (Monros et al. 2001; Percy 2008). Some of the 
latter group have mutations in other genes, such as that 
of the cyclin-dependent kinase-like 5 (CDKL5), which is 
described in individuals with an early seizure onset vari-
ant of RTT (Kalscheuer et al. 2003) or the forkhead box 
G1 (FOXG1), which is responsible for the congenital vari-
ant of RTT (Ariani et al. 2008). However, there remains 
a subset of patients with a clinical diagnosis of RTT who 
are mutation-negative for all the aforementioned genes. 
Next generation sequencing (NGS) has emerged as a 
potentially powerful tool for the study of such genetic dis-
eases (Zhu et al. 2015).
Herein, we report the use of a family based exome 
sequencing approach in a cohort of 20 families with clini-
cal features of RTT, but without mutations in the usually 
studied genes. We establish the neurological relevance of 
the newly identified candidate genes by assessing them in 
Caenorhabditis elegans model.
Materials and methods
Patient samples
A cohort of 19 Spanish parent–child trios and one fam-
ily with two affected daughters who exhibited clinical 
features associated with RTT were recruited at Sant Joan 
de Deu Hospital in Barcelona, Catalonia, Spain. These 
patients had been diagnosed on the basis of the usual 
clinical parameters (Monros et al. 2001), and accord-
ing to the recently revised RettSearch International Con-
sortium criteria and nomenclature (Neul et al. 2010), but 
were found to be mutation-negative for MECP2, CDKL5 
and FOXG1 in the original single-gene screening. The 
parents were clinically evaluated and it was not observed 
any evidence of intellectual disability. Genomic DNA 
from these patients was extracted from peripheral blood 
leukocytes using standard techniques, and analyzed by 
exome sequencing at the Cancer Epigenetics and Biology 
Program (PEBC) in Barcelona, Catalonia, Spain. Ethical 
approval for the molecular genetic studies was obtained 
from each institutional review board.
Whole exome sequencing and Sanger validation
Coding regions were captured using the TruSeq DNA Sam-
ple Preparation and Exome Enrichment Kit (Illumina, San 
Diego, California). Paired-end 100 × 2 sequences were 
sequenced with the Illumina HiScan SQ system at the 
National Center for Genomic Analysis in Barcelona. We 
also included the exome sequencing data of an MECP2, a 
CDKL5 and a JMJD1C (Sáez et al. 2016) RTT-associated 
family for data processing to improve the de novo single 
nucleotide variant calling. The complete exome sequenc-
ing data of all the studied samples are available from the 
Sequence Read Archive (http://www.ncbi.nlm.nih.gov/sra) 
with the ID: SRP073424 (private link for the reviewer until 
publication: http://www.ncbi.nlm.nih.gov/sra/SRP073424). 
The overall coverage statistics for each individual of the 
families, considering the regions captures using Exome 
Enrichment Kit, and number of reads in the position of the 
variation is shown in Supplementary Table 1. The identified 
variants were validated by Sanger sequencing using a Big-
Dye® Terminator v3.1 Cycle Sequencing Kit in an Applied 
Biosystems 3730/DNA Analyzer. The raw data were ana-
lyzed with Codon Code Aligner Software. The primers 
used for Sanger sequencing are shown in Supplementary 
Table 2.
Caenorhabditis elegans handling
The techniques used for the culture of Caenorhabditis 
elegans were essentially as described (Brenner 1974). The 
worms were backcrossed at least three times to avoid back-
ground mutations. The behavior of three sets of ten animals 
was independently assessed in locomotion assays without 
food that were performed at 20 °C, as previously described 
(Sawin et al. 2000).
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Results
Clinical criteria for selecting RTT trios
The 21 patients (derived from the 20 families studied) 
included in this study fulfilled the recently revised clinical 
criteria for the diagnosis of RTT following the usual clini-
cal parameters (Monros et al. 2001), and the RettSearch 
International Consortium criteria and nomenclature (Neul 
et al. 2010). Specifically, all patients presented stereotypic 
hand movements, 90.5 % of them (19/21) showed micro-
cephaly and also presented onset of the first signs of the 
disease before the age of 12 months. 66.7 % of patients 
(14/21) acquired motor skills, while a further seven 
(33.3 %), who had a more severe phenotype, never walked. 
Language skills were progressively lost in 28.6 % of the 
patients and 71.4 % of them (15/21) never acquired them. 
Additionally, important episodes of epilepsy were expe-
rienced by 81.0 % of the patients (17/21), and 57.1 % of 
them (12/21) manifested apneas and/or hyperventilation.
Bioinformatic process for filtering and selecting 
pathogenic variants
Before their inclusion in this study, patients underwent an 
extensive clinical and genetic work-up to detect genetic 
alterations in MECP2, CDKL5, and FOXG1. However, no 
molecular diagnosis could be established. We performed 
whole exome sequencing (WES) on the 61 individuals 
(20 pairs of healthy parents and 21 affected daughters) 
separately by subjecting whole blood derived genomic 
DNA to exome enrichment and sequencing. We focused 
our analysis on de novo single nucleotide variants (SNVs) 
due to their known relevance in autism and mental retar-
dation-related diseases (Vissers et al. 2010). On average, 
WES gave rise to 419,045 variants, including SNVs and 
indels, of which 19,951 non-synonymous variants per fam-
ily (4.7 %) were predicted to have a functional impact on 
the genomic sequence. To select variants that had not pre-
viously been described in the healthy population, we fil-
tered out the variants with an allele frequency of 1 % or 
higher (the classic definition of a polymorphism) formerly 
observed in the Single Nucleotide Polymorphism database 
(dbSNP) and the 1000 Genomes Pilot Project data. After-
wards, to focus on de novo inheritance, patients’ variants 
were filtered first against variants found in their own par-
ents and then against a pool of controls comprising all 
the healthy parents included in the study. Following this 
process, we achieved an average of 106 SNVs per fam-
ily, which corresponded to 81 mutated genes per family. 
De novo candidate variants were selected on the basis of 
the quality of the alignments, damage score predictors and 
the conservation level of each of the genes during evolu-
tion. The complete exome sequencing data of all the stud-
ied samples are available from the Sequence Read Archive 
(http://www.ncbi.nlm.nih.gov/sra).
The global yield of genomic analysis following the bio-
informatic process described herein enabled 22 coding 
de novo mutations to be identified in 66.7 % (14 of 21) 
of Rett-like patients: 20 SNVs and 2 indels. The identi-
fied variants and their de novo status were confirmed by 
conventional Sanger sequencing. Illustrative samples are 
shown in Fig. 1. Interestingly, in seven (33.3 %) of the 
studied RTT probands, exome sequencing did not detect 
any genetic change relative to their respective parents. The 
clinical characteristics of these seven patients without obvi-
ous pathogenic variants are summarized in Table 1. In one 
of the families, there were two affected children, and an 
analysis of potentially relevant recessive variants was per-
formed. For the recessive analysis, and following the same 
criteria to define a variant as deleterious, we selected the 
variants with homozygous recessive genotype, and then at 
the gene level, we also selected the genes presenting more 
than one heterozygotic variant in the same gene (com-
pound heterozygosity). We did not find any candidate gene 
consistent with the phenotype of the family with the two 
affected sisters.
Variants in genes previously associated 
with neurodevelopmental disorders
Of the 22 identified coding de novo mutations in the 
assessed RTT-like patients, five (22.7 %) occurred in genes 
previously associated with neurodevelopmental disorders 
that presented a clinicopathological phenotype with fea-
tures coinciding with those of Rett syndrome (Table 2). In 
particular, we identified four mutations in genes such as 
HCN1 (Nava et al. 2014) and GRIN2B (Endele et al. 2010; 
Lemke et al. 2014), which are associated with early infan-
tile epileptic encephalopathy; SLC6A1, which is associ-
ated with epilepsy and myoclonic-atonic seizures (Carvill 
et al. 2015); TCF4, which is associated with Pitt–Hopkins 
syndrome (Sweatt 2013); and SCN1A, which is associ-
ated with Dravet syndrome (Brunklaus and Zuberi 2014) 
(Table 2). The clinical characteristics of these five patients 
with variants in genes previously associated with neu-
rodevelopmental phenotypes are summarized in Table 3. 
A comparison of the clinical features of our RTT-like 
patients, where we have identified mutations in candidate 
genes previously associated with other neurodevelopmen-
tal disorders, with those observed for these diseases is 
summarized in Table 4.
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Variants in genes previously not associated 
with neurodevelopmental disorders
Of the 22 identified coding de novo variants in the RTT-
like patients assessed here, 17 (77.3 %) occurred in genes 
that had not previously been associated with neurodevelop-
mental disorders (Table 5). However, two of these variants 
were associated with non-neurodevelopmental disorders: a 
BTBD9 variant linked to restless leg syndrome (Kemlink 
et al. 2009), and an ATP8B1 SNV associated with familial 
cholestasis (Klomp et al. 2004), respectively. Interestingly, 
the BTBD9 variant was detected in the same patient that 
carried the SCN1A variant associated with Dravet syndrome 
(Table 2). The other 15 potentially pathogenic variants 
identified occurred in genes that had not been linked to any 
genetic disorder of any type. However, there was an enrich-
ment of genes with a potential role in neuronal biology 
and functionality, such as the gamma-aminobutyric type 
c.856C>T 
p.Gly286Ser
ZNF620
c.1699G>A 
p.Ala567Ser
GABBR2
Father Mother Proband
PDLIM7
c.1222C>T p.Asp408Asn
Fig. 1  Sanger sequencing validation of the de novo variants identified by exome sequencing. Illustrative examples for ZNF620 (c.856C > T 
p.Gly286Ser), GABBR2 (c.1699G > A p.Ala567Ser) and PDLIM7 (c.1222C > T p.Asp408Asn) are shown
Table 1  Clinical summary of patients without exome candidates
Clinical scores of our series of patients according to Pineda scale. Severity classification ranges from 0 to 4 as follows: age of onset of first 
signs (1: >24 months; 2: 12–24 months; 3: 0–12 months), microcephaly (0: absent; 1: present), sitting alone (1: acquired < 8 months; 2: seat and 
mantains; 3: seat and lost), ambulation (0: acquired < 18 months, 1: acquired < 30 months; 2: acquired > 30 months; 3: lost acquisition; 4: never 
acquired), respiratory function (0: no dysfunction; 1: hyperventilation and/or apnea), epilepsy (0: absent; 1: present and controlled; 2: uncon-
trolled or early epilepsy), hands use (0: acquired and conserved; 1: acquired and partially conserved; 2: acquired and lost; 3: never acquired), 
onset of stereotypies (1: > 10 years, 2: > 36 months; 3: 18-36 months) and languages (0: preserved and propositive; 1: lost; 2: never acquired). 
The total score is the sum of the scores of each clinical feature
Proband Age (years) Onset of 
signs
Micro-
cephaly
Sitting 
alone
Ambula-
tion
Respira-
tory func-
tion
Epilepsy Hand use Stereotyp-
ies
Language Total score
1 15 1 1 1 1 0 1 1 1 1 8
2 28 3 1 1 0 1 2 2 3 2 15
5.1 7 3 1 3 4 1 0 3 2 2 19
5.2 5 3 1 1 2 0 0 2 3 2 14
7 16 2 1 0 0 0 2 1 2 1 9
15 8 3 0 1 2 0 2 1 1 1 10
18 3.5 3 1 1 1 0 0 1 3 0 10
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B receptor subunit 2 (GABBR2), the neuronal acetylcho-
line receptor subunit alpha-5 (CHRNA5), the Huntington-
associated protein 1 (HAP1), the axon guider semaphorin 
6B, the ankyrin repeat containing proteins ANKRD31 and 
AGAP6, and the neuronal voltage-gated calcium channel 
CACNA1 (Table 5). Proband 14 was a particularly interest-
ing case in which four potential pathogenic variants were 
present, affecting zinc finger (ZNF620), a nucleolar com-
plex (NOC3L), G patch domain (GPATCH2) and GRAM 
domain (GRAMD1A)-related proteins (Table 5). The clini-
cal characteristics of these patients with variants in genes 
previously not associated with neurodevelopmental disor-
ders are summarized in Table 6.
Neurological phenotype of candidate genes in C. elegans
To demonstrate a neurological effect for a loss of function 
of the detected genes that had not previously been asso-
ciated with neurodevelopmental disorders (Table 5), we 
used the model organism C. elegans to confirm the geno-
type-phenotype correlation. We obtained all the available 
C. elegans mutants that carry deleterious mutations in the 
orthologous genes to those human genes with potentially 
pathogenic mutations in the patients. In this model, back-
crossing is a commonly used procedure to obtain a specific 
mutant strain without any secondary mutations from its 
genetic composition. Under these conditions, we were able 
to test six available mutant strains that were backcrossed 
at least three times to prove that any observed phenotype 
was really associated to specific mutations in the ortholo-
gous genes. To this end, we studied the C. elegans mutants 
carrying deleterious mutations in the gene orthologs of the 
human genes PDLIM7, ANKRD31, ZNF620, CHRNA5, 
MGRN1 and GABBR2 described in Table 7. Consider-
ing that the loss of normal movement and coordination is 
one of the clearest signs shown by Rett patients, we per-
formed a locomotion assay of the nematodes as previously 
described (Sawin et al. 2000), using the wild-type N2 strain 
as a control (Supplementary Video 1). We observed that in 
83.3 % (5 of 6) of the cases the mutation of the ortholog 
of the human exome sequencing identified genes in C. ele-
gans exhibited a locomotion defective phenotype (Fig. 2). 
The most severe phenotypes were represented by alp-1, 
unc-44 and pag-3, with mutations in the orthologs of PDZ 
and LIM domain protein 7 (PDLIM7), ankyrin repeat con-
taining protein ANKRD31 and the zinc protein ZNF620, 
respectively (Fig. 2 and Supplementary Videos 2, 3 and 
4). The case of alp-1 was particularly interesting, because 
mutant worms were not only thinner than usual and com-
pletely locomotion defective, but they exhibited transitory 
spasms. Significant defects, such as slower locomotion 
and uncoordinated movement, were also observed in the 
mutants of unc-63 and C11H1.3, the C. elegans orthologs Ta
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of the genes coding for the neuronal acetylcholine receptor 
subunit alpha-5 (CHRNA5) and mahogunin RING finger 
protein 1 (MGRN1), respectively. Although we did not find 
a clear locomotion defect in the gbb-2 mutant (the ortholog 
of GABBR2) (Fig. 2), it occurs in the gbb-1;gbb-2 double 
mutant (Dittman and Kaplan 2008), gbb-1 being the C. 
elegans ortholog of GABBR1 (gamma-aminobutyric acid 
type B receptor subunit 1). The clinical picture of the par-
ticular RTT cases with mutations in the genes studied in C. 
elegans is shown in Table 6.
Discussion
Our results indicate that the existence of de novo vari-
ants in genes with potential neurological functionalities, 
such as neuronal receptors (GABBR2 and CHRNA5), 
axon guiders (SEMA6B), synaptic ionic channels (CAC-
NA1I) and others, contribute to the development of 
RTT-like clinical phenotypes in the context of wild-type 
sequences for standard Rett genes such as MECP2 and 
FOXG1. These patients share most of the clinicopatho-
logical features of classic RTT syndrome, such as stereo-
typic hand movements, relative microcephaly, and onset 
of the disease after the age of 12 months. Thus, exome 
sequencing is a powerful tool for genetically character-
izing these enigmatic cases. In this regard, once a new 
candidate gene has been identified, it is now possible to 
design specific sequencing strategies for the molecular 
screening of this particular target in larger populations 
of patients with intellectual disability. The strategy based 
on exome sequencing patients who have RTT features, 
but no known mutations in the usual genes, has recently 
been used in other smaller series of patients (Grillo et al. 
2013; Okamoto et al. 2015; Hara et al. 2015; Olson et al. 
2015; Lopes et al. 2016). Most importantly, our study 
and the aforementioned previous reports strengthen the 
concept that a mutational heterogeneous profile hit-
ting shared neurological signaling pathways contributes 
to RTT-like syndromes. Examples of confluence in the 
same molecular crossroads include the gamma-amin-
obutyric type B receptor subunit 2 (GABBR2) de novo 
variant, described here, and the formerly identified vari-
ant in the gamma-aminobutyric acid receptor delta gene 
(GABRD) (Hara et al. 2015). Interestingly, a second RTT-
like patient has been identified as being a carrier of a de 
novo GABBR2 variant (Lopes et al. 2016), highlighting 
the likelihood that this gene and pathway contribute to 
the clinical entity. Another example of similarly targeted 
genes in RTT-like patients is that of the proteins con-
taining ankyrin-repeats that are involved in postsynaptic 
density (Durand et al. 2007). This study has revealed de 
novo variants in the ankyrin repeat containing proteins 
AGAP6 and ANKRD31 in RTT-like patients, and the pres-
ence of de novo variant of the SH3 and multiple ankyrin 
repeat domain3 protein (SHANK3) (Hara et al. 2015) and 
ankyrin-3 (ANK3) (Grillo et al. 2013) has been reported in 
two RTT-like patients. A final example of the convergence 
of cellular pathways to provide a common RTT-like phe-
notype is represented by the disruption of the ionic chan-
nels. We found the existence of a voltage-gated calcium 
channel subunit alpha 11 (CANA1I) de novo variant in an 
RTT-like patient. Additionally, the presence of de novo 
variants in the calcium release channel RYR1 (Grillo et al. 
2013) and the sodium voltage-gated channel alpha subu-
nit 2 (SCN2A) (Baasch et al. 2014) in two other RTT-like 
Table 3  Clinical summary of the patients with variants in genes previously associated with neurodevelopmental phenotypes
Clinical scores of our series of patients according to Pineda scale. Severity classification ranges from 0 to 4 as follows: age of onset of first signs 
(1: > 24 months; 2: 12–24 months; 3: 0–12 months), microcephaly (0: absent; 1: present), sitting alone (1: acquired < 8 months; 2: seat and 
mantains; 3: seat and lost), ambulation (0: acquired < 18 months, 1: acquired < 30 months; 2: acquired > 30 months; 3: lost acquisition; 4: never 
acquired), respiratory function (0: no dysfunction; 1: hyperventilation and/or apnea), epilepsy (0: absent; 1: present and controlled; 2: uncon-
trolled or early epilepsy), hands use (0: acquired and conserved; 1: acquired and partially conserved; 2: acquired and lost; 3: never acquired), 
onset of stereotypies (1: > 10 years, 2: > 36 months; 3: 18-36 months) and languages (0: preserved and propositive; 1: lost; 2: never acquired). 
The total score is the sum of the scores of each clinical feature
Proband Gene vari-
ant
Age 
(years)
Onset of 
the signs
Micro-
cephaly
Sitting 
alone
Ambula-
tion
Respira-
tory func-
tion
Epilepsy Hand use Stereo-
typies
Language Total 
score
4 HCN1 24 3 1 1 3 1 2 3 1 2 16
8 SCN1A, 
MGRN1, 
BTBD9
7 3 1 1 4 1 2 1 3 2 18
10 TCF4 16 3 1 1 2 1 2 1 1 2 14
11 GRIN2B, 
SEMA6B
3 2 0 1 3 0 1 1 1 2 10
17 SLC6A1 36 3 0 1 1 0 1 1 1 0 7
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probands have been reported. It is also intriguing that in 
our study a variant in HAP was found, whereas in simi-
lar series heterozygous variants in huntingtin (HTT) have 
been described (Lopes et al. 2016; Rodan et al. 2016), fur-
ther reinforcing the links between Huntington’s disease 
and Rett syndrome (Roux et al. 2012). Another interest-
ing case is provided by TCF4, which is associated with 
Pitt–Hopkins syndrome (Sweatt 2013), where in addition 
to our study, others have found mutations in RTT-like 
patients (Lopes et al. 2016). This observation could be of 
interest for clinicians due to phenotypic similitudes such 
as intellectual disability, stereotypic movement, apneas 
and seizures (Marangi et al. 2012).
Our findings also suggest that a substantial degree of 
clinical overlap can exist between the features associated 
with RTT and those of other neurodevelopmental disor-
ders. Our exome sequencing effort indicated that probands 
originally diagnosed as RTT-like patients were, in fact, 
carriers of well-known pathogenic de novo mutations 
linked to Dravet Syndrome (SCN1A), myoclonic-atonic 
epilepsy (SCLC6A1), or early infantile epileptic encepha-
lopathies 24 (HCN1) and 27 (GRIN2B). The purely clinical 
classification of these patients, without a thorough genetic 
study, can be difficult because some of these patients are 
composites that carry at least two pathogenic variants. For 
example, in our cases, the Dravet syndrome patient also 
had a de novo variant in BTBD9 associated with the devel-
opment of restless leg syndrome. In addition, among the 
newly identified candidate genes associated with RTT-like 
features, a few of these patients simultaneously carried 
two de novo variants (e.g., probands 8, 19 and 21), further 
complicating the tasks of correctly diagnosing and manag-
ing these individuals.
Finally, the studies performed in C. elegans validate the 
functional relevance for nervous system function of the 
newly proposed candidate genes. Future studies would be 
necessary to assess the role of the specific variants identi-
fied, such as rescuing the defects with the expression of 
normal cDNAs versus cDNAs containing the mutation, ide-
ally using cDNAs of human origin to prove similar func-
tion of the gene in the two species. It is also relevant to 
mention that for some of the newly reported mutated genes 
in our RTT-like patients, there are mice models targeting 
the described loci that show neurological phenotypes such 
as BTBD9 (motor restlessness and sleep disturbances) 
(DeAndrade et al. 2012), MGRN1 (spongiform neurode-
generation) (He et al. 2003), SEMA6B (aberrant mossy 
fibers) (Tawarayama et al. 2010), CHRNA5 (alterations 
in the habenulo-interpeduncular pathway) (Fowler et al. 
2011), GABBR2 (anxiety and depression-related behav-
ior) (Mombereau et al. 2005) and HAP1 (depressive-like 
behavior and reduced hippocampal neurogenesis) (Chan 
et al. 2002; Xiang et al. 2015).Ta
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Table 6  Clinical summary of patients with variants in new candidate disease genes
Clinical scores of our series of patients according to Pineda scale. Severity classification ranges from 0 to 4 as follows: age of onset of first 
signs (1: >24 months; 2: 12–24 months; 3: 0–12 months), microcephaly (0: absent; 1: present), sitting alone (1: acquired < 8 months; 2: seat and 
mantains; 3: seat and lost), ambulation (0: acquired < 18 months, 1: acquired < 30 months; 2: acquired > 30 months; 3: lost acquisition; 4: never 
acquired), respiratory function (0: no dysfunction; 1: hyperventilation and/or apnea), epilepsy (0: absent; 1: present and controlled; 2: uncon-
trolled or early epilepsy), hands use (0: acquired and conserved; 1: acquired and partially conserved; 2: acquired and lost; 3: never acquired), 
onset of stereotypies (1: > 10 years, 2: > 36 months; 3: 18–36 months) and languages (0: preserved and propositive; 1: lost; 2: never acquired). 
The total score is the sum of the scores of each clinical feature
Proband Gene variant Age 
(years)
Onset of 
the signs
Micro-
cephaly
Sitting 
alone
Ambu-
lation
Res-
piratory 
function
Epilepsy Hand use Stereo-
typies
Lan-
guage
Total 
score
3 AGAP6 14 3 1 2 4 1 1 3 2 2 19
8 SCN1A, 
MGRN1, 
BTBD9
7 3 1 1 4 1 2 1 3 2 18
11 GRIN2B, 
SEMA6B
3 2 0 1 3 0 1 1 1 2 10
12 VASH2 11 3 1 1 4 1 0 2 2 1 15
13 CHRNA5 10 3 1 2 4 1 1 2 3 2 19
14 ZNF620, 
GRAMD1A, 
NOC3L, 
GPATCH2
2 3 1 1 2 0 1 3 2 2 15
19 GABBR2, 
ATP8B1
2 3 1 1 4 0 0 3 2 2 16
20 HAP1 24 3 1 1 1 1 0 2 2 1 12
21 PDLIM7, 
SRRM3
5 3 1 3 4 0 1 2 1 2 17
22 ANKRD31 17 3 0 1 2 0 1 2 3 2 14
23 CACNA1I 1/8 3 1 1 2 1 0 3 3 2 16
Table 7  Phenotype in Caenorhabditis elegans
Human gene Ortholog in 
C.elegans
Similarity (%) Identity (%) Mutation in 
C.elegans
Locomotion 
phenotype
Neurological 
phenotypes
Other phenotypes
GABBR2 gbb-2 53 34 Deletion normal Hypersensitivity 
to aldicarb
–
MGRN1 C11H1.3 58 41 Deletion locomotion defec-
tive
– –
CHRNA5 unc-63 58 40 Deletion locomotion defec-
tive
Uncoordinated 
locomotion with 
strong levami-
sole resistance
–
ZNF620 pag-3 65 47 Deletion locomotion defec-
tive
Altered neuro-
secretion and 
up-regulation 
of DCV (Dense 
Core Vesicles) 
components
–
ANKRD31 unc-44 59 39 Deletion locomotion defec-
tive
Asymmetric 
dynamics of 
axonal and den-
dritic microtu-
bules defects
–
PDLIM7 alp-1 65 47 Deletion locomotion defec-
tive
– Defects in 
actin filament 
organization in 
muscle cells
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Conclusions
Overall, this study demonstrates the genetic mutational 
diversity that underlies the clinical diagnosis of patients 
with clinical features that resemble RTT cases. Once the 
recognized MECP2, CDKL5 and FOXG1 mutations have 
been discarded, exome sequencing emerges as a very use-
ful strategy for the more accurate classification of these 
patients. The de novo variants identified by this approach 
can modify the first diagnostic orientation towards another 
neurodevelopmental disorder, or pinpoint new genes 
involved in the onset of RTT-like features. Interestingly, 
most of these new targets are involved in the same func-
tional networks associated with correct neuronal function-
ality. Further research is required to understand the role 
of these proteins in the occurrence of neurodevelopmental 
diseases. Additional functional experiments, such as the C. 
elegans assays used in this study, would be extremely help-
ful for this purpose.
Acknowledgments The research leading to these results has received 
funding from the People Programme (Marie Curie Actions) of the 
European Union’s Seventh Framework Programme FP7/2012 under 
REA Grant agreement PITN-GA-2012-316758 of the EPITRAIN 
project and PITN-GA-2009–238242 of DISCHROM; the E-RARE 
EuroRETT network (Carlos III Health Institute project PI071327); the 
Foundation Lejeune (France); the Cellex Foundation; the Botín Foun-
dation; the Finestrelles Foundation; the Catalan Association for Rett 
Syndrome; and the Health and Science Departments of the Catalan 
government (Generalitat de Catalunya). M.E. is an ICREA Research 
Professor.
Compliance with ethical statement 
Conflict of interest The authors declare that there is no conflict of 
interest associated with this manuscript.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
Ariani F et al (2008) FOXG1 is responsible for the congenital variant 
of Rett syndrome. Am J Hum Genet 83:89–93
Baasch AL et al (2014) Exome sequencing identifies a de novo 
SCN2A mutation in a patient with intractable seizures, severe 
intellectual disability, optic atrophy, muscular hypotonia, and 
brain abnormalities. Epilepsia 55:e25–e29
Brenner S (1974) The genetics of Caenorhabditis elegans. Genetics 
77:71–94
Brunklaus A, Zuberi SM (2014) Dravet syndrome–from epileptic 
encephalopathy to channelopathy. Epilepsia 55:979–984
Carvill GL et al (2015) Mutations in the GABA transporter SLC6A1 
cause epilepsy with myoclonic-atonic seizures. Am J Hum Genet 
96:808–815
Chahrour M, Zoghbi HY (2007) The story of Rett syndrome: from 
clinic to neurobiology. Neuron 56:422–437
Chan EY et al (2002) Targeted disruption of Huntingtin-associated 
protein-1 (Hap1) results in postnatal death due to depressed 
feeding behavior. Hum Mol Genet 11:945–959
Christodoulou J, Grimm A, Maher T, Bennetts B (2003) RettBASE: 
the IRSA MECP2 Variation Database—a new mutation database 
in evolution. Hum Mutat 21:466–472
DeAndrade MP et al (2012) Motor restlessness, sleep disturbances, 
thermal sensory alterations and elevated serum iron levels in 
Btbd9 mutant mice. Hum Mol Genet 21:3984–3992
Dittman JS, Kaplan JM (2008) Behavioral impact of neurotrans-
mitter-activated G-protein-coupled receptors: muscarinic and 
GABAB receptors regulate Caenorhabditis elegans locomotion. 
J Neurosci 28:7104–7112
Durand CM et al (2007) Mutations in the gene encoding the synaptic 
scaffolding protein SHANK3 are associated with autism spec-
trum disorders. Nat Genet 39:25–27
Endele S et al (2010) Mutations in GRIN2A and GRIN2B encoding 
regulatory subunits of NMDA receptors cause variable neurode-
velopmental phenotypes. Nat Genet 42:1021–1026
Fowler CD, Lu Q, Johnson PM, Marks MJ, Kenny PJ (2011) Habenu-
lar α5 nicotinic receptor subunit signalling controls nicotine 
intake. Nature 471:597–601
Grillo E et al (2013) Revealing the complexity of a monogenic dis-
ease: Rett syndrome exome sequencing. PLoS One 8:e56599
Hara M, Ohba C, Yamashita Y, Saitsu H, Matsumoto N, Matsui-
shi T (2015) De novo SHANK3 mutation causes Rett syn-
drome-like phenotype in a female patient. Am J Med Genet A 
167:1593–1596
Fig. 2  Locomotion assay in Caenorhabditis elegans. Functional vali-
dation of mutations was performed by measuring the locomotion rate, 
expressed in average of measuring, in C. elegans. Each mutant strain 
was compared to a wild-type N2 control strain by measuring worm 
body bends during 20 s in three independent sets of experiments. 
Locomotion rates of mutants, represented by C11H1.3 (MGRN1), 
unc-63 (CHRNA5), pag-3 (ZNF620), unc-44 (ANKRD31) and alp-1 
(PDLIM7) are significantly lower compared to that of the N2 control 
strain (p < 0.0001), on the contrary gbb-2 (GABBR2) mutant move 
similarly. Standard error of the mean (SEM) values is shown. p values 
obtained according to Student’s t test. ***p < 0.0001
1354 Hum Genet (2016) 135:1343–1354
1 3
He L et al (2003) Spongiform degeneration in mahoganoid mutant 
mice. Science 299:710–712
Kalscheuer VM et al (2003) Disruption of the serine/threonine kinase 
9 gene causes severe X-linked infantile spasms and mental retar-
dation. Am J Hum Genet 72:1401–1411
Kemlink D et al (2009) Replication of restless legs syndrome loci in 
three European populations. J Med Genet 46:315–318
Klomp LW et al (2004) Characterization of mutations in ATP8B1 
associated with hereditary cholestasis. Hepatology 40:27–38
Lemke JR et al (2014) GRIN2B mutations in West syndrome 
and intellectual disability with focal epilepsy. Ann Neurol 
75:147–154
Lewis JD, Meehan RR, Henzel WJ, Maurer-Fogy I, Jeppesen P, Klein 
F, Bird A (1992) Purification, sequence, and cellular localization 
of a novel chromosomal protein that binds to methylated DNA. 
Cell 69:905–914
Lopes F et al (2016) Identification of novel genetic causes of Rett 
syndrome-like phenotypes. J Med Genet 53:190–199
Marangi G et al (2012) Proposal of a clinical score for the molec-
ular test for Pitt-Hopkins syndrome. Am J Med Genet A 
158A:1604–1611
Mombereau C, Kaupmann K, Gassmann M, Bettler B, van der Putten 
H, Cryan JF (2005) Altered anxiety and depression-related 
behaviour in mice lacking GABAB(2) receptor subunits. Neu-
roReport 16:307–310
Monrós E, Armstrong J, Aibar E, Poo P, Canós I, Pineda M (2001) 
Rett syndrome in Spain: mutation analysis and clinical correla-
tions. Brain Dev 23:S251–S253
Nava C et al (2014) De novo mutations in HCN1 cause early infantile 
epileptic encephalopathy. Nat Genet 46:640–645
Neul JL et al (2010) Rett syndrome: revised diagnostic criteria and 
nomenclature. Ann Neurol 68:944–950
Okamoto N et al (2015) Targeted next-generation sequencing in 
the diagnosis of neurodevelopmental disorders. Clin Genet 
88:288–292
Olson HE et al (2015) Mutations in epilepsy and intellectual disabil-
ity genes in patients with features of Rett syndrome. Am J Med 
Genet A 167A:2017–2025
Percy AK (2008) Rett syndrome: recent research progress. J Child 
Neurol 23:543–549
Rett A (1966) On an unusual brain atrophy syndrome in hyperam-
monemia in childhood. Wien Med Wochenschr 116:723–772
Rodan LH et al (2016) A novel neurodevelopmental disorder asso-
ciated with compound heterozygous variants in the huntingtin 
gene. Eur J Hum Genet. doi:10.1038/ejhg.2016.74
Roux JC, Zala D, Panayotis N, Borges-Correia A, Saudou F, Vil-
lard L (2012) Modification of Mecp2 dosage alters axonal 
transport through the Huntingtin/Hap1 pathway. Neurobiol Dis 
45:786–795
Sáez MA et al (2016) Mutations in JMJD1C are involved in Rett syn-
drome and intellectual disability. Genet Med 18:378–385
Sawin ER, Ranganathan R, Horvitz HR (2000) C. elegans locomo-
tory rate is modulated by the environment through a dopaminer-
gic pathway and by experience through a serotonergic pathway. 
Neuron 26:619–631
Sweatt JD (2013) Pitt-Hopkins syndrome: intellectual disability due 
to loss of TCF4-regulated gene transcription. Exp Mol Med 
45:e21
Tawarayama H, Yoshida Y, Suto F, Mitchell KJ, Fujisawa H (2010) 
Roles of semaphorin-6B and plexin-A2 in lamina-restricted pro-
jection of hippocampal mossy fibers. J Neurosci 30:7049–7060
Vissers LE et al (2010) A de novo paradigm for mental retardation. 
Nat Genet 42:1109–1112
Xiang J, Yan S, Li SH, Li XJ (2015) Postnatal loss of hap1 reduces 
hippocampal neurogenesis and causes adult depressive-like 
behavior in mice. PLoS Genet 11:e1005175
Zhu X et al (2015) Whole-exome sequencing in undiagnosed genetic 
disorders: interpreting 119 trios. Genet Med 17:774–781
